Zhou You-Feng, Huang Yan, Liu Guang-Hua
Department of Pediatrics, Fujian Provincial Maternity and Children's Hospital, The Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Department of Children's Healthcare, Fujian Provincial Maternity and Children's Hospital, The Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Front Pharmacol. 2022 Apr 20;13:810617. doi: 10.3389/fphar.2022.810617. eCollection 2022.
This meta-analysis aims to evaluate the effect of levetiracetam on serum C-reactive protein (CRP) in children with epilepsy. Articles published up to April 15, 2021 were searched from Google Scholar databases, PubMed, Science Direct, Springer, Wiely, NIH and Baidu Scholar databases to analyzed the difference of serum CRP in epilepsy children compared to healthy controls, and the effect of levetiracetam on serum CRP in children with epilepsy was also assessed. All the included studies met the inclusion criteria. 103 publications were selected and eight articles were included in this study with sample size = 246. The serum CRP level in childhood epilepsy was significantly higher than the healthy controls (pooled standardized mean difference (SMD): 6.930, 95% CI: 2.716-11.143, z = 3.22, < 0.01). A significant level of between-study heterogeneity was found (τ = 17.911, Chi = 148.67, df = 3, < 0.01, I = 98.0%). Besides, serum CRP level was significantly decreased by the treatment of levetiracetam in childhood epilepsy (pooled SMD: 3.505, 95% CI: 1.638-5.373, z = 3.68, < 0.01). A significant level of between-study heterogeneity was found (τ = 4.346, Chi = 97.17, df = 4, < 0.01, I = 95.9%). The funnel plot showed there was no significant publication bias in the meta-analysis. Serum CRP levels are upregulated in childhood epilepsy and reduced by levetiracetam in children with epilepsy.
本荟萃分析旨在评估左乙拉西坦对癫痫患儿血清C反应蛋白（CRP）的影响。从谷歌学术数据库、PubMed、科学Direct、Springer、Wiely、美国国立医学图书馆和百度学术数据库中检索截至2021年4月15日发表的文章，以分析癫痫患儿与健康对照者血清CRP的差异，并评估左乙拉西坦对癫痫患儿血清CRP的影响。所有纳入研究均符合纳入标准。共筛选出103篇文献，本研究纳入8篇文章，样本量为246。儿童癫痫患者的血清CRP水平显著高于健康对照者（合并标准化均数差（SMD）：6.930，95%可信区间：2.716 - 11.143，z = 3.22，P < 0.01）。研究间存在显著的异质性（τ = 17.911，卡方 = 148.67，自由度 = 3，P < 0.01，I² = 98.0%）。此外，左乙拉西坦治疗可使儿童癫痫患者的血清CRP水平显著降低（合并SMD：3.505，95%可信区间：1.638 - 5.373，z = 3.68，P < 0.01）。研究间存在显著的异质性（τ = 4.346，卡方 = 97.17，自由度 = 4，P < 0.01，I² = 95.9%）。漏斗图显示荟萃分析中无显著的发表偏倚。儿童癫痫患者血清CRP水平上调，而左乙拉西坦可使其降低。
